On August 14, 2023, a group of four senior executives from our company visited Xiamen Hongai Hospital.
Xiamen Hongai Hospital is a tertiary non-profit general hospital funded by the Renai Medical Foundation, initiated and led by C&D Corporation. As the first hospital in China to have an accelerator boron neutron capture therapy device, Hongai Hospital has completed the first phase of clinical treatment for 14 patients. Under the hospital's reception, we have gained a deeper understanding of the therapeutic effects of boron neutron capture therapy device and its application prospects in the field of oncology.
During the reception, the hospital secretary introduced in detail the therapeutic effects, indications, and future development prospects of the boron neutron capture therapy device. The device uses neutron beams generated by an accelerator to accurately hit tumor cells, thereby achieving the goal of precise treatment of tumors. Compared with traditional radiotherapy and chemotherapy, boron neutron capture therapy has lower side effects and higher cure rate. He said that the boron neutron capture therapy device introduced by Hongai Hospital is the first accelerator device to enter the clinical trial stage. Hongai Hospital is one of the first medical institutions in China to carry out neutron clinical trials, providing new treatment options for domestic tumor patients.
Our senior executives expressed great interest in the boron neutron capture therapy device at Hongai Hospital, and had in-depth exchanges with the hospital on its technical details, clinical applications, and potential for future cooperation. We agreed that the introduction of this technology will have a profound impact on the domestic tumor treatment field and bring good news to the majority of patients. At the same time, our company also looks forward to further cooperation with Xiamen Hongai Hospital and Zhongpeng Medical to jointly promote the application and development of neutron therapy technology in China.